Anti-SARS-CoV-2 S1 (RBD) Neutralizing Antibody (V3S-0723-XY12) (CAT#: V3S-0723-XY12)

Send Inquiry
  • fig1

Datasheet

MSDS

COA

Summary
Property
Applications
Protocols
Target

Summary

Description This product 87G7 is a receptor-blocking human monoclonal antibody. It retained potent in vitro neutralizing activity against SARS-CoV-2 variants including the Alpha, Beta, Gamma, Delta and Omicron VOCs. 87G7 exhibits potent neutralizing efficacy against Wuhan-Hu-1 S mediated cell entry. 87G7 could also protect mice and hamsters prophylactically against challenge with all current SARS-CoV-2 VOCs, and shows therapeutic activity against SARS-CoV-2 challenge in both animal models.
Clonality Monoclonal
Host Species Human
Target Species SARS-CoV-2 (Alpha, Beta, Gamma, Delta, Omicron BA.1 and BA.2)
Immunogen SARS-CoV-2 spike protein
Epitope An epitope containing residues Y421, L455, F456, F486 and Y489 of RBD domain.
Isotype IgG1 kappa

Property

Expression Species HEK293F or CHO cell line
Conjugation Unconjugated
Purity >95%
Endotoxin <1 EU/mg
Form Liquid
Purification Protein A purified
Sterility 0.2 μM filtered
Formulation PBS, pH 7.4
Preservation No preservatives
Stabilizer No stabilizers
Storage Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics.

Applications

Application ELISA; BLI; Neut
Application Notes 87G7 was found to block the binding of recombinant S trimer to ACE2 by BLI and ELISA-based assay. ELISA: The antibody started at 10 μg/mL with a serial 1:5 dilution. Bio-layer interferometry (BLI): The biosensor tips were immersed into a well containing mAb (50 μg/mL) for 15 min.
Live virus neutralization: 87G7 potently neutralized D614G (IC50: 5.7 ng/ml), Wuhan-Hu-1 (IC50: 5.4 ng/ml), Lambda and Mu variants (IC50s: 1.2 and 4.8 ng/ml, respectively),as well as Alpha, Beta, Gamma, Delta and Omicron (BA.1/BA.2) with IC50 values ranging from 3.1 to 12.5 ng/ml.

Protocols

ELISA Enzyme-Linked Immunosorbent Assay Protocol
WB Western Blot Protocol
FC Flow Cytometry Protocol

Target

Target SARS-CoV-2 S1
Alternative Name Severe acute respiratory syndrome coronavirus 2 Spike S1
Research Area Coronavirus Disease 2019
Related Disease Coronavirus Disease 2019
For research use only, not directly for clinical use.
banner banner
© 2024 Creative Biolabs. All Rights Reserved.
antibody
Online Inquiry